9.13
price up icon5.92%   0.51
after-market Handel nachbörslich: 9.13
loading
Schlusskurs vom Vortag:
$8.62
Offen:
$8.56
24-Stunden-Volumen:
304.44K
Relative Volume:
1.31
Marktkapitalisierung:
$432.88M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
-9.9239
EPS:
-0.92
Netto-Cashflow:
$-9.60M
1W Leistung:
+4.58%
1M Leistung:
-2.77%
6M Leistung:
+5.43%
1J Leistung:
-2.25%
1-Tages-Spanne:
Value
$8.52
$9.18
1-Wochen-Bereich:
Value
$8.44
$9.18
52-Wochen-Spanne:
Value
$7.44
$10.90

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name
Firmenname
Theravance Biopharma Inc
Name
Telefon
650-808-6000
Name
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Name
Mitarbeiter
99
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
TBPH's Discussions on Twitter

Vergleichen Sie TBPH mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TBPH
Theravance Biopharma Inc
9.13 432.88M 62.02M -45.65M -9.60M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-06 Herabstufung Leerink Partners Outperform → Market Perform
2024-04-12 Eingeleitet BTIG Research Buy
2024-01-08 Herabstufung Evercore ISI Outperform → In-line
2022-05-23 Eingeleitet SVB Leerink Outperform
2021-11-05 Hochstufung JP Morgan Underweight → Neutral
2021-09-15 Herabstufung JP Morgan Overweight → Underweight
2021-08-25 Herabstufung Morgan Stanley Overweight → Underweight
2021-08-24 Herabstufung Cowen Outperform → Market Perform
2020-10-14 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-07-07 Eingeleitet JP Morgan Overweight
2020-06-15 Eingeleitet Morgan Stanley Equal-Weight
2020-05-13 Eingeleitet Cowen Outperform
2020-01-08 Bestätigt H.C. Wainwright Buy
2019-11-06 Hochstufung Robert W. Baird Underperform → Neutral
2019-10-29 Eingeleitet H.C. Wainwright Buy
2018-03-29 Fortgesetzt Piper Jaffray Overweight
2017-08-17 Eingeleitet Evercore ISI Outperform
2017-06-16 Eingeleitet Cantor Fitzgerald Overweight
2017-05-11 Bestätigt Needham Buy
2016-12-21 Eingeleitet Needham Buy
2016-11-03 Eingeleitet Piper Jaffray Overweight
2016-10-12 Herabstufung Robert W. Baird Neutral → Underperform
2016-08-03 Herabstufung BofA/Merrill Neutral → Underperform
2016-06-20 Eingeleitet Guggenheim Buy
2016-06-20 Bestätigt Leerink Partners Outperform
2016-05-12 Eingeleitet Leerink Partners Outperform
2016-05-05 Herabstufung BofA/Merrill Buy → Neutral
2015-02-03 Hochstufung Robert W. Baird Underperform → Neutral
Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

pulisher
Apr 20, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Alliancebernstein L.P. - Defense World

Apr 20, 2025
pulisher
Apr 19, 2025

(TBPH) Trading Signals - news.stocktradersdaily.com

Apr 19, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 17, 2025
pulisher
Apr 14, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Position Trimmed by Corebridge Financial Inc. - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Wellington Management Group LLP Raises Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Acquires New Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

American Century Companies Inc. Acquires 8,289 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects - Investing.com Canada

Apr 11, 2025
pulisher
Apr 07, 2025

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire

Apr 07, 2025
pulisher
Apr 03, 2025

Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 03, 2025
pulisher
Apr 03, 2025

Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN

Apr 03, 2025
pulisher
Mar 31, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Longview News-Journal

Mar 31, 2025
pulisher
Mar 31, 2025

Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Has $2.77 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire

Mar 27, 2025
pulisher
Mar 25, 2025

Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 25, 2025
pulisher
Mar 25, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

(TBPH) Investment Analysis - news.stocktradersdaily.com

Mar 23, 2025
pulisher
Mar 18, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World

Mar 18, 2025
pulisher
Mar 10, 2025

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha

Mar 10, 2025
pulisher
Mar 08, 2025

Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Theravance Biopharma, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 04, 2025

Zacks Research Brokers Lower Earnings Estimates for TBPH - Armenian Reporter

Mar 04, 2025
pulisher
Mar 03, 2025

What is Zacks Research’s Forecast for TBPH Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Where are the Opportunities in (TBPH) - news.stocktradersdaily.com

Mar 02, 2025
pulisher
Mar 01, 2025

Equities Analysts Issue Forecasts for TBPH FY2028 Earnings - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Misses Estimates By $0.26 EPS - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025
pulisher
Feb 27, 2025

FY2024 Earnings Forecast for TBPH Issued By HC Wainwright - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH) - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

What is HC Wainwright’s Estimate for TBPH FY2028 Earnings? - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

Theravance Biopharma Reports Record 2024 Financial Results - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Theravance Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Feb 26, 2025
pulisher
Feb 26, 2025

Theravance Biopharma Inc Reports Q4 2024 Earnings: YUPELRI Sales - GuruFocus

Feb 26, 2025
pulisher
Feb 25, 2025

Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20 - GuruFocus

Feb 25, 2025
pulisher
Feb 25, 2025

Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result - Yahoo Finance

Feb 25, 2025
pulisher
Feb 25, 2025

Theravance Biopharma: Strategic Milestones and Revenue Forecasts Justify Buy Rating - TipRanks

Feb 25, 2025

Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):